

CLAIMS

1. A percutaneously absorbable preparation comprising a salt-form acidic drug and an addition salt compound of a basic substance.

2. The percutaneously absorbable preparation according to claim 1, wherein the addition salt compound of the basic substance is blended at the range of from 0.5 to 10 fold mole based on the salt-form acidic drug.

3. The percutaneously absorbable preparation according to claim 1 or 2, wherein the addition salt compounds of the basic substance are salts of ammonium compounds.

4. The percutaneously absorbable preparation according to claims 1 to 3, wherein the percutaneously absorbable preparation is a nonaqueous preparation.

5. The percutaneously absorbable preparation according to claims 1 to 4, wherein the percutaneously absorbable preparation is a matrix-type patch or an ointment.

6. The percutaneously absorbable preparation according to claims 1 to 5, wherein the salt-form acidic drug is an anti-inflammatory drug or a muscular relaxant drug.

7. The percutaneously absorbable preparation according to claim 6, wherein the salt-form acidic drug is an anti-inflammatory drug and the addition salt compound of the basic substance is combined at the range of from 0.5 to 7 fold mole based on the anti-inflammatory drug having salt-form.

8. The percutaneously absorbable preparation according to claims 1 to 7, which is a matrix-type percutaneously absorbable preparation, wherein the anti-inflammatory drug having salt-form and the addition salt compound of the basic

substance are contained in an adhesive basis layer.

9. The matrix-type percutaneously absorbable preparation according to claim 8, wherein the adhesive basis layer is composed of one or more than two of styrene-isoprene-styrene block copolymer, polyisobutylene and acrylic adhesive.

10. A percutaneous absorption accelerating composition of the salt-form acidic drug, which contains the addition salt compound of the basic substance.

11. The percutaneous absorption accelerating composition according to claim 10, wherein the addition salt compounds of the basic substance are salts of ammonium compounds.

12. The percutaneous absorption accelerating composition according to claim 10 or 11, wherein the salt-form acidic drug is an anti-inflammatory drug.